Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay

Journal of Diabetes Investigation

Volumn 7, Issue 3, 2016, Pages 324-331

  Matsuo, Toshihiro ^a   Miyagawa, Jun ichiro ^a   Kusunoki, Yoshiki ^a   Miuchi, Masayuki ^a   Ikawa, Takashi ^a   Akagami, Takafumi ^a   Tokuda, Masaru ^a   Katsuno, Tomoyuki ^a   Kushida, Akira ^b   Inagaki, Takashi ^b   Namba, Mitsuyoshi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Cosmic Corporation ^*  (Japan)

Author keywords

Glucagon (1 29); Glucagon like peptides; Type 2 diabetes mellitus

Indexed keywords

GLICENTIN; GLUCAGON; GLUCOSE; MINIGLUCAGON[19-29]; MONOCLONAL ANTIBODY; PROGLUCAGON; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLUCAGONEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RADIOIMMUNOASSAY KIT; REPRODUCIBILITY; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCAGON; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; PROGLUCAGON; YOUNG ADULT;

EID: 84940094605     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12400     Document Type: Article

References (39)

1. Holst JJ. Enteroglucagon. Annu Rev Physiol 1997; 59: 257-271.
2. Larsen PJ, Tang-Christensen M, Holst JJ, et al. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997; 77: 257-270.
3. Munõz BL, Rufener C, Srikant CB, et al. Immunocytochemical evidence for glucagon-containing cells in the human stomach. Horm Metab Res 1977; 9: 37-39.
4. Rouillé Y, Westermark G, Martin SK, et al. Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells. Proc Natl Acad Sci U S A 1994; 91: 3242-3246.
5. Dhanvantari S, Seidah NG, Brubaker PL. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol 1996; 10: 342-355.
6. Tucker JD, Dhanvantari S, Brubaker PL. Proglucagon processing in islet and intestinal cell lines. Regul Pept 1996; 62: 29-35.
7. Yabe D, Kuroe A, Watanabe K, et al. Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. J Diabetes Complications 2015; 29: 413-421.
8. Henkel E, Menschikowski M, Koehler C, et al. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Metabolism 2005; 54: 1168-1173.
9. Kozawa J, Okita K, Iwahashi H, et al. Early postprandial glucagon surge affects postprandial glucose levels in obese and non-obese patients with type 2 diabetes. Endocr J 2013; 60: 813-818.
10. Müller WA, Faloona GR, Aguilar-Parada E, et al. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970; 283: 109-115.
11. Kawai K, Murayama Y, Okuda Y, et al. Postprandial glucose, insulin and glucagon responses to meals with different nutrient compositions in non-insulin-dependent diabetes mellitus. Endocrinol Jpn 1987; 34: 745-753.
12. Bataille D, Dalle S. The forgotten members of the glucagon family. Diabetes Res Clin Pract 2014; 106: 1-10.
13. Bataille D. Pro-protein convertases in intermediary metabolism: islet hormones, brain/gut hormones and integrated physiology. J Mol Med 2007; 85: 673-684.
14. Blache P, Kervran A, Le-Nguyen D, et al. Miniglucagon production from glucagon: an extracellular processing of a hormone used as a prohormone. Biochimie 1994; 76: 295-299.
15. Blache P, Kervran A, Dufour M, et al. Glucagon (19-29), a Ca2 + pump inhibitory peptide, is processed from glucagon in the rat liver plasma membrane by a thiol endopeptidase. J Biol Chem 1990; 265: 21514-21519.
16. Thim L, Moody AJ. The primary structure of porcine glicentin (proglucagon). Regul Pept 1981; 2: 139-150.
17. Baldissera FG, Holst JJ. Glicentin 1-61 probably represents a major fraction of glucagon-related peptides in plasma of anaesthetized uraemic pigs. Diabetologia 1986; 29: 462-467.
18. Holst JJ. Evidence that glicentin contains the entire sequence of glucagon. Biochem J 1980; 187: 337-343.
19. Bak MJ, Albrechtsen NW, Pedersen J, et al. Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. Eur J Endocrinol 2014; 170: 529-538.
20. Wewer Albrechtsen NJ, Hartmann B, Veedfald S, et al. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia 2014; 57: 1919-1926.
21. Mercodia AB. (Internal company date). Available from: http://www.mercodia.se/ Accessed May 13, 2014.
22. EuroDiagnostica. (Internal company date). Available from: http://www.eurodiagnostica.com/ Accessed May 13, 2014.
23. Merck Millipore Corp. (Internal company date). Available from: http://www.merckmillipore.com/ Accessed May 13, 2014.
24. Knop FK, Vilsbøll T, Larsen S, et al. Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis. Regul Pept 2010; 164: 144-150.
25. Bagger JI, Knop FK, Lund A, et al. Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. Diabetologia 2014; 57: 1720-1725.
26. Harada N, Hamasaki A, Yamane S, et al. Plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels after glucose loading are associated with different factors in Japanese subjects. J Diabetes Investig 2011; 2: 193-199.
27. Unger RH, Dobbs RE, Orci L. Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. Annu Rev Physiol 1978; 40: 307-343.
28. Koh DS, Cho JH, Chen L. Paracrine interactions within islets of Langerhans. J Mol Neurosci 2012; 48: 429-440.
29. Naito H, Ohneda A, Kojima R, et al. Plasma glicentin in diabetic and gastrectomized patients. Regul Pept 1999; 79: 55-61.
30. Laferrère B, Swerdlow N, Bawa B, et al. Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 4072-4076.
31. Trebbien R, Klarskov L, Olesen M, et al. Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs. Am J Physiol Endocrinol Metab 2004; 287: 431-438.
32. Robertson MD, Livesey G, Morgan LM, et al. The influence of the colon on postprandial glucagon-like peptide 1 (7-36) amide concentration in man. J Endocrinol 1999; 161: 25-31.
33. Kärvestedt L, Andersson G, Efendic S, et al. A rapid increase in beta-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment. J Intern Med 2002; 251: 307-316.
34. de Galan BE, Tack CJ, Lenders JW, et al. Theophylline improves hypoglycemia unawareness in type 1 diabetes. Diabetes 2002; 51: 790-796.
35. Marina AL, Utzschneider KM, Wright LA, et al. Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function. Diabetes Care 2012; 35: 1119-1125.
36. Calanna S, Urbano F, Piro S, et al. Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in metabolic syndrome. Eur J Endocrinol 2012; 166: 917-922.
37. Meier JJ, Deacon CF, Schmidt WE, et al. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Diabetologia 2007; 50: 806-813.
38. Christensen M, Vedtofte L, Holst JJ, et al. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011; 60: 3103-3109.
39. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig 2010; 1: 8-23.